In colon cancer, GFAT inhibitors reduce O‐GlcNAcylation, suppressing mTOR activation, while OGA knockdown (KD) elevates O‐GlcNAcylation, enhancing mTOR signalling and tumour progression.60 This evidence concerns the gene OGA and neoplasm.